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Abstract  
 
Myelodysplastic syndromes (MDS) are a group of clonal bone marrow 
(BM) disorders characterized by hematopoietic insufficiency and potential 
leukemic transformation. Recent studies suggest a substantial increase in BM 
vascularity of MDS and acute myeloid leukemia (AML). However, the 
mechanisms that regulate angiogenesis and angiogenic factors role in MDS 
progression are poorly understood. In this study, we hypothesized that changes 
in MDS BM microenvironment can induce BM angiogenesis leading to AML 
onset and progression. 
Bone marrow biopsies were colleted from patients; we analysed 19 MDS 
patients that were not under treatment at the time of analysis and 9 patients 
under MDS treatment (like Thalidomide, Danazol and Vidaza). 
Flow cytometry analysis of BM biopsies revealed an increase in CD34+, 
CD117+ and CD133+ progenitor cells, CD133+KDR+ EPC and KDR+ endothelial 
cells (EC) in intermediate risk patients (accordingly with the International 
Prognostic Scoring System (IPSS) classification). Patients under MDS 
therapeutics had lower progenitor cells levels when compared with patients 
without treatment. Secondary MDS caused by radiotherapy had augmented 
CD133+ progenitor cells, CD133+KDR+ EPC and KDR+ EC. The incidence of 
apoptosis of AC133+ progenitor cells and KDR+ EC in intermediate risk patients 
was higher than in low risk patients. These data revealed an increase in 
progenitor cell pool (or increased turnover of this lineage), in particular EPCs, 
with disease progression, and with radiotherapy MDS related, which seems to 
be reduced with specific therapeutics for MDS. BM microvessel density 
quantifications were made, indicating that intermediate risk patients had higher 
levels of the angiogenic markers: VEGF, CD31 and vWF (that is, increased BM 
MVD and increased VEGF levels). 
To understand how the MDS BM microenvironment might contribute to 
leukemic transformation, we measured the expression of factors like TNF-α, 
TFG-β and PlGF by Real-Time PCR as well as the different VEGF isoforms. We 
also determined VEGF levels by ELISA in BM plasma samples.   
 III 
 TNF-α and TFG-β expression was higher in intermediate-risk MDS 
patients and VEGF levels were similar among patients.  We also observed that 
the proportion between VEGF isoforms changed. In MDS patients the most 
frequent isoform was VEGF121 and there was an increase in VEGF189 with MDS 
progression. Together, these results confirmed an abnormal BM environment in 
MDS patients may be due to a particular regulation of angiogenic factors and 
augmented angiogenesis which might contribute to leukemic progression.  
To determine whether AC133+ progenitor cells are already transformed in 
MDS early stages (ie. are part of the malignant process), we isolated AC133+ 
cells from a low-risk MDS patient with a chromosomal deletion del(20q). Using 
FISH analysis, we detected this cytogenetic alteration in some of those cells, 
which is strongly suggestive of an early progenitor cell transformation. We also 
performed immnohistochemistry analysis for the EPC marker homeobox HoxA9 
in the same cells and we conclude that subset of EPC are transformed (ie. 
malignant) cells in MDS.   
Besides these Human studies, we tried to validate the importance and 
putative involvement of EPC/vascular cells in MDS-leukemia progression in a 
murine model of irradiation-induced BM malignant transformation. In this model, 
mice that develop BM disease (MDS-leukemia) earlier had lowering EPC levels, 
again suggesting that EPC turnover is a crucial feature of the pathophysiology 
of these BM diseases.   
Taken together, these findings suggest that an increase in the BM 
progenitor cell pool is directly related with MDS clinical stage risk and may 
contribute to the angiogenic response in MDS. The altered microenvironment 
and malignant cell transformation can also lead to disease progression and 
leukemia onset.  The presence of an EPC malignant clone in MDS BM may 
indicate a possible role of these cells in BM abnormal vascularization, but also 
in the disruption of normal hematopoiesis and, finally, acute leukemia 
progression.  
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Resumo 
 
Os síndromes Mielodisplásicos (SMD) são um grupo de doenças clonais 
da medula óssea (MO), caracterizadas por uma desregulação na hematopoiese 
e susceptibilidade em desenvolver leucemia mieloide aguda (LMA). A maioria 
dos doentes têm uma idade média de 65 anos e acaba por falecer, a maior 
parte das vezes, antes de desenvolver leucemia. A mielodisplasia pode surgir 
de novo ou ser secundária devido a tratamentos de radioterapia ou 
quimioterapia.  
Os SMD podem resultar de alterações genéticas e epigenéticas que 
ocorrem nas células progenitoras hematopoieticas e de alterações no micro-
ambiente da MO. As alterações genéticas mais frequentes são as 
cromossomais que surgem em 50% dos casos de SMD primários e 80% nos 
secundários. O micro-ambiente medular, pode potenciar o desenvolvimento do 
clone maligno devido sobretudo aos níveis patológicos das citoquinas 
secretadas.  
A angiogénese nos tumores hematológicos não está tão bem 
caracterizada como nos tumores sólidos. Contudo há evidências de um 
aumento da vasculatura da MO em SMD e em LMA. Algumas drogas anti-
angiogenénicas como a Talidomida já são usadas clinicamente e com sucesso 
em doentes específicos. Contudo, os mecanismos que regulam a angiogénese 
e a produção de factores angiogénicos na progressão da mielodisplasia são 
pouco conhecidos. A caracterização do perfil angiogenico destes doentes é 
importante para o prognóstico, diagnóstico e avaliação das respostas 
terapêuticas.  
Neste estudo colocamos a hipótese de as alterações no micro-ambiente 
da MO dos doentes com SMD poderem conduzir a LMA.  
Foram recolhidos os aspirados medulares dos doentes dos quais 19 não 
tinham recebido nenhuma terapêutica e 9 estavam em tratamento para a 
mielodisplasia (com Talidomida, Danazol e Vidaza). 
Análises por citometria de fluxo nas MO mostraram que as células 
progenitoras para os marcadores CD34+, CD117+ e CD133+, células 
progenitoras endoteliais (CPE) CD133+KDR+ e células endoteliais (CE) KDR+ 
nos doentes com risco intermédio (de acordo com a classificação do 
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International Prognostic Scoring System (IPSS)) existem em maior 
percentagem. Nos doentes em tratamento a percentagem destas células era 
menor quando comparada à percentagem dos doentes sem tratamento. Os 
SMD secundários causados por tratamento anterior com radioterapia têm um 
número aumentado de células progenitoras CD133+, CPE CD133+KDR+ e CE 
KDR+. Também foram medidos os níveis de apoptose nas células da MO 
destes doentes. Os doentes de risco intermédio apresentam níveis de apoptose 
mais elevados nas células progenitoras CD133+ e CE KDR+ que os doentes de 
baixo risco. Estes resultados sugerem um aumento de células progenitoras, em 
particular CPE, um aumento dos vasos sanguíneos na MO que acompanha a 
progressão da doença, nos doentes sem tratamento e expostos previamente à 
radioterapia. Pelo contrário, estes valores parecem ser reduzidos nos doentes 
em tratamento específico para a mielodisplasia.     
Para perceber de que modo o micro-ambiente medular pode contribuir 
para a transformação em leucemia, foi determinada a expressão do mRNA, por 
PCR Quantitativo, nos seguintes factores angiogenicos: TNF-α, TFG-β e PlGF. 
Também foi medida a expressão das isoformas do VEGF por PCR Quantitativo 
e os níveis totais de VEGF por ELISA nas células da MO. 
A expressão de TNF-α e TFG-β era maior nos doentes com risco 
intermédio. Verificou-se que o padrão da expressão das isoformas do VEGF 
estava alterado; a isoforma VEGF121 estava aumentada e a isoform VEGF189 
aumentava com a progressão da doença. Análises de imunohistoquímica com 
marcadores de vasos sanguíneos nomeadamente VEGF, CD31 e vWF 
revelaram um aumento de vasos nos doentes de risco intermédio 
comparativamente aos doentes de baixo risco. Estes resultados sugerem um 
aumento da angiogenese nos doentes com SMD, bem como uma regulação 
alterado de factores no micro-ambiente da MO que podem contribuir para a 
progressão da doença em LMA.   
Para perceber se as CEP poderiam também ser células participantes no 
processo de transformação maligna, isolaram-se células progenitoras AC133+ 
de um paciente com uma delecção no cromossoma 20 (del(20q)). Usando 
técnicas de FISH foram detectadas células com a alteração citogenética, 
revelando assim uma transformação em células progenitoras. Estas células 
foram posteriormente submetidas a um ensaio de imunohistoquímica para o 
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marcador de CPE HoxA9, do qual se concluiu que uma parte das CPE estarão 
provavelmente envolvidas no processo de transformação maligna em SMD. 
Além dos estudos em humanos tentou-se validar a importância do 
envolvimento das CEP na progressão de SMD para leucemia usando para isso 
um modelo de carcinogénese em ratinho induzido por irradiação. O grupo de 
ratinhos que ficou doente mais cedo apresentou um menor número de CPE em 
circulação no sangue periférico que o grupo que não desenvolveu doença. Isto 
sugere uma contribuição das CPE na génese de algumas doenças 
hematológicas tais como SMD e leucemia aguda.    
 
Concluindo, estes resultados sugerem que uma maior renovação 
(“turnover”) de progenitores medulares está directamente relacionado com o 
grupo de risco dos SMD, podendo originar uma resposta angiogenica na MO 
do SMD. Um micro-ambiente medular alterado e a presença de uma CEP 
transformada podem originar um aumento dos vasos sanguíneos e a uma 
alteração da hematopoiese normal podendo culminar no desenvolvimento da 
LMA.    
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 1 
Aims 
 
 
 
1) To characterize the angiogenic profile in MDS patients according 
with the International Prognostic Scoring System (IPSS) 
classification. 
 
 
 
2) To contribute towards a better understanding the involvement of 
bone marrow endothelial progenitor cells and soluble angiogenic 
factors in the origin of the angiogenic response in MDS bone 
marrow. 
 
 
 
3) To test the “common origin of malignant hematopoietic and 
vascular cells hypothesis” in MDS.  
 
 
 
4) Development and characterization of a murine model of MDS, in 
order to validate the biological readouts investigated in the previous 
aims. 
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1) Introduction 
 
Basic mechanisms of carcinogenesis  
 
Carcinogenesis is a multistep process in which normal cells undergo 
vascular and functional changes, resulting in their conversion into neoplastic 
ones. Several genetics alterations are acquired in this process due to mutations 
in genes with dominant gain of function, oncogenes, and inactivating mutations 
in tumor suppressor genes leading to genetic instability. During neoplasic 
transformation cell physiology is altered, resulting in the acquisition of distinct 
properties responsible and essential for tumor progression: augmented 
proliferative potential and self-sufficiency in growth signals, apoptosis evading 
and insensitivity to anti-growth signals, induction of tumor angiogenesis and 
invasion/metastasis dissemination. It is believed that most human tumors share 
these characteristics although each tumor may acquire them by various 
mechanisms.1,2 
 
Angiogenesis    
 
Mechanism 
 
Angiogenesis is a process that results in the growth of new blood 
vessels. During embryonic development, vasculogenesis/angiogenesis 
establishes the primary vascular tree and provides the nutrients and oxygen 
needed for organ development. During adulthood, angiogenesis occurs in 
physiologic processes, such as during the ovarian cycle and placenta 
development, and in pathological processes like wound healing and cancer.3  
 
Tissue metabolic demands in nutrients and oxygen comprise the main 
stimulus for blood vessel growth. Oxygen can diffuse to a distance of 100-
200µm, but above that limit a hypoxic environment is originated; exposure of 
cells to a hypoxic environment is the best known molecular “trigger” for the 
onset of angiogenesis.  
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For instance, hypoxia is a strong inducer of angiogeneic stimulators, 
including vascular endothelial growth factor (VEGF). VEGF is one of the best 
characterized angiogenic factors, which has a potent action at several steps of 
the angiogenic process: vessel permeability, endothelial cell proliferation and 
migration and vessel chemoattraction fusion pre-existing structures. Alternative 
splicing generates six VEGF-A isoforms consisting of 121, 165, 145, 189 and 
206 amino acids which differ mostly in their bioavailability (ie, some isoforms 
are freely soluble whereas others bind collagen or heparin). VEGF121 is a fully 
soluble isoform whereas VEGF165 can exists either in the soluble isoform or 
trapped in the membrane, VEGF145 and the largest isoforms VEGF189 and 
VEGF206 because their affinity for cell-surface proteoglycan are membrane 
isoforms.4 While VEGF121, VEGF165 and VEGF189 stimulate endothelial cell 
proliferation and migration in adult angiogenesis, VEGF206 appears to be 
expressed only in embryonic tissue. The largest VEGF isoforms are responsible 
for prolonged mitogenic signals than the shorter isoforms, which are more 
diffusible.5  
VEGF binds to three known tyrosine kinase receptors: Flt-1/VEGFR-1, 
KDR/Flk-1/VEGFR-2 and Flt-4/VEGFR-3. These receptors differ mainly in their 
cell pattern of expression, and also in their binding specification (the 3 receptors 
bind members of the VEGF family with different affiliation).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1. Interactions between VEGF ligands and receptors.   
From Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23:1011-1027  
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Adult Vasculogenesis 
 
Vasculogenesis is the de novo formation of blood vessels from the 
differentiation of endothelial precursors. In the embryo, endothelial cells arise 
from mesodermal precursor cells, the angioblasts, to form the primitive 
capillarity network. Embryonic vasculogenesis involve the fusion of multiple 
blood islands. These, are spatially arranged with hematopoietic stem cells that 
are going to origin hematopoietic (blood) cells at the center of the blood island 
and endothelial progenitor cells (EPC) at the periphery. These progenitors have 
the capacity of differentiating into functional mature endothelial cells.6  
Some studies revealed that HSC and EPC may have a common 
ancestor, the hemangioblast.7 HSC and EPC express common surface markers 
like KDR (VEGFR2), CD34 and Sca-1. EPCs were initially isolated using KDR 
and CD34 as markers, but more recently, it was shown that EPC expressed 
also the stem cell marker AC133 (whose function is still undisclosed); 
interestingly, the expression of AC133 in EPC is lost when cells differentiate into 
mature endothelial cells.8 EPC maturation and differentiation is crucial to form 
functional endothelial cells and consequently blood vessels. The potential to 
differentiate into EC is regulated by several signalling pathways including 
Notch/Delta.9  Notch/Delta signalling regulates embryonic arterial 
differentiation10 and in postnatal vasculature regulates arterial EC 
differentiation.11 Concerning the activation of an endothelial-specific 
transcription profile, recent evidence as suggested the Hox family of 
transcription factors may be involved. In fact, the homeobox transcription factor 
HoxA9, which is regulated by histone deacetylases, is also a critical regulator of 
adult neovascularization and directs the expression of other endothelial specific 
genes.12  
Indeed, neovascularization in the adult was though to be maintained only 
by sprouting angiogenesis. However, there is recent evidence that suggested 
EPC in adult blood and bone marrow are involved in angiogenesis by replacing 
lost endothelial cells; EPC have been shown to incorporate healing wounds and 
even tumor vasculature.14 The pathways and mechanisms that regulate EPC 
differentiation are important also for post-natal angiogenesis.  
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Tumor angiogenesis 
 
In the early 70s Judah Folkman proposed that angiogenesis is required 
for tumor growth after a 1 to 2 mm3 volume (which formed the basis for the 
research in hypoxia regulation of neo-angiogenesis). He also postulated that 
angiogenic inhibition would be a good strategy to prevent tumor development. It 
was showed that if angiogenesis was prevented tumor growth decreased and 
tumor cells died.15    
As mentioned early, avascular tumors grow until inner regions become 
hypoxic which leads to the angiogenic stimuli. In normal conditions, or even in 
some tumors, maintenance of a quiescent vasculature results from a balance 
between angiogenic activators and inhibitors, between proliferation and 
apoptosis.  The loss of equilibrium between such activators and inhibitors such 
as in response to hypoxia, results in an angiogenic “switch”, favouring 
proliferation and blood vessels growth, eventually contributing towards tumor 
cells dissemination (metastases). Angiogenic inhibitors identified to date include 
endostatin (it is a fragment from type XVIII collagen and blocks VEGF 
signalling, though its binding to VEGF receptor 2); angiostatin (it is a fragment 
from plasminogen and links to hepatocit growth factor receptor), 
thrombospondin-1 (binds to p53 and alter its regulation) and tumstatin (derived 
from type IV collagen degradation, binds integrins which avoid their connection 
to endothelial cells and their migration).16 
 
Mechanistically, tumors use the same molecules used in normal 
angiogenesis to promote their own blood supply. Globally, tumor vascularization 
may occur by several mechanisms such as sprouting, recruitment of EPC, 
cooption, vasculogenic mimicry and mosaic vessels.17 Blood vessels can 
growth through sprouting which results in the branching of new capillaries from 
pre-existing vessels or non-sprouting processes like fusion of pre-existing 
vessels.18  
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 In addition, recent years have shown that molecular therapeutic 
strategies to block this process have potential in the treatment of murine and 
human tumors. Most notably, VEGF blockade has shown significant success in 
the treatment of colo-rectal and renal cancer. 19 
The neovascularization process is crucial for tumor growth and 
survival.15,20 Given the recent identified involvement of EPC in the angiogenesis 
process, it is important to understand the mechanisms that regulate endothelial 
cells growth from EPC in order to identify new anti-angiogenic therapeutic 
thargets. In a vascular stress situation, these precursor cells are recruited to the 
circulation and, mediated by angiogenic inducers and inhibitors; they 
incorporate the new formed vessels (or may contribute towards vessel 
formation in an indirect manner).  
 
 
 
 
 
 
 
 
Figure2. Vascular angiogenic mechanisms: sprouting (A), EPC recruitment (B), cooption (C), 
vasculogenic mimicry (D) and mosaic vessels (E). 
From Auguste, P., et al, Crit Rev Oncol Hematol, 2005; 54:53-61 
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Hematopoietic organs: The Bone Marrow 
 
Structure 
 
 Bone marrow is the major hematopoietic organ in adulthood and exists in 
the central bone cavities of long and axial bones. Marrow spaces form a 
trabecular structure with stromal cells, hematopoietic and endothelial 
progenitors. In long bones, one or two large vessels (arteries and veins) enter 
the marrow cavity and in flat bones there are several blood vessels with 
different sizes. Myelinated and non-myelinated nerves constitute BM 
enervation. The hematopoietic tissue consists in various types of mature blood 
cells and their immature precursors, organized in a spatially, temporally and 
molecularly ordered manner. 21  
The bone marrow microenvironment consists of BM stroma cells and 
factors, growth factors and cytokines, provided from stroma and blood vessels. 
Stromal cells have been considered the responsible in maintaining the BM 
microenvironment but the vasculature is also seen as very important since it 
provides the BM with oxygen and nutrients.  Globally, the BM stroma is thought 
to consist of different types of cells: endothelial cells, macrophages, 
adypocytes, fibroblasts, osteoblasts and extracellular matrix elements like 
fibronectin.22  
For hematopoiesis to take place it is necessary a stable 
microenvironment where stem cells are located in their appropriate niches, 
where they are provided with the factors for self-renewal, proliferation, 
migration, differentiation and lineage commitment. Hematopoietic stem cells 
self-renewal and proliferation are maintained by low level secretion of stromal 
cells factors and others. Hematopoiesis is stimulated by up-regulation of 
specific cytokines in response of hypoxia, anemia, inflammation or bacterial 
infection.23  
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Hematopoiesis 
 
 Hematopoiesis is a continuous process that starts with a pluripotent 
hematopoietic stem cell. It has been suggested that this cell may originate non-
hematopoietic cells including hepatocytes, neurons, osteoblast, adipocytes, 
condrocytes and fibroblasts. The commitment, proliferation and differentiation of 
hematopoietic cells are controlled by cytokines, growth factors, hormones and 
the activation of a global (cell-specific) transcriptional profile. After maturation, 
cells transverse blood vessels wall and enter the bloodstream, in response to 
chemoattractant signals. 
 Pluripotent HSC have the capacity to maintain their number through a 
self-renewal process and the potential to commit to the myeloid and lymphoid 
lineages if the BM microenvironment provides the right conditions. HSC may 
originate a common myeloid precursor – CMP – and a common lymphoid 
precursor – CLP. CMP can develop into a granulocytic and monocytic precursor 
– GMP, or a erytroid and megakaryocyte precursor – EMP. GMP can 
differentiate into monocytes and neutrophils and EMP gives rise to erytrocytes 
and megakaryocytes. CLP differentiate in B lymphocytes and pro-T 
lymphocytes.23 importantly, the process of myeloid/hematopoietic differentiation 
results also from the balance between survival and differentiation signals and 
apoptosis control within the BM microenvironment.  
 
As mentioned before, HSC and EPC have been suggested to share a 
common ancestor. It is believed that, in the adult, the majority of EPC reside in 
BM in association with HSC and BM stroma. EPCs incorporate nascent 
vasculature of pathological lesions (tumor angiogenesis) but the precise signals 
required for EPC recruitment from the BM and differentiation are not completely 
understood; however, ischemia and vascular trauma stimulate EPC 
mobilization.6,14 It is also known that upregulation of VEGF165 and Angiopoetin 1 
results in mobilization of endothelial and hematopoietic progenitors.24 
Tumor angiogenesis may be supported by the co-mobilization of HSC 
and EPC from bone marrow and incorporation of EPC in the tumor 
vasculature.25 EPCs have been already detected in circulation of lymphoma 
patients8,26 and other haematological diseases like leukemia.27 Since these 
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originate in the BM microenvironment it is extremely important understand how 
EPC contribute for vasculogenesis in haematological malignancies and its role 
in the genesis of BM diseases.  
 
Myelodysplastic Syndromes  
 
Disease description 
 
The Myelodysplastic syndromes (MDS) are a heterogeneous group of 
disorders of hematopoietic stem cells that are characterized by ineffective 
hematopoiesis and susceptibility to development into acute myelogenous 
leukemias.28 Most patients with this die before leukemia progression due to BM 
failure, infections or hemorrhagic complications.   
MDS is seldom observed in patients under 50 years old but it is the most 
frequent hematologic disease in patients between 60 and 70 years old. Above 
70 years old disease incidence is about 50 cases per 100.000 per year. Several 
risk factors are implicated in the MDS genesis: age, alcohol, cigarette smoking, 
ionizing radiation among others. Myelodysplasia may arise de novo or may be 
secondary due to previous radiotherapy or chemotherapy treatments (therapy-
related MDS).29    
 
Classification systems  
 
In 1982, the French-American-British (FAB) group established the first 
classification of MDS and defined 5 subtypes based on morphology, the number 
of blasts in bone marrow and peripheral blood and monocyte counts. MDS 
patients were then classified as having refractory anemia (RA; <5% marrow 
blasts), RA with ringed sideroblasts (RARS; <5% marrow blasts >15% BM 
ringed sideroblasts), RA with excess of blasts (RAEB; 5-20% marrow blasts), 
RAEB in transformation (RAEB-T; 21-30% marrow blasts) and chronic 
myelomonocytic leukaemia (CMML; <5% marrow blasts, > 103/mm3 
monocytes). Although, the FAB classification provides important diagnostic 
prognostic information, patients with single or multiple cytopenias, other than 
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anemia could not be easily classified; also, controversy persisted about the 
number of BM blasts needed for AML diagnosis.  
To overcome some of this limitations, in 2001 the World Health 
Organization (WHO) classification suggested new subtypes of MDS. Refractory 
anemia (RA) and RA with ringed sideroblasts (RARS), were kept but new 
subtypes were introduced such as refractory cytopenia with multiple displasia 
(RCMD), RCMD with ringed sideroblasts (RCMD-RS). RA with excess of blasts 
I (RAEB-I; 5-10% blasts in BM) and RA with excess of blasts II (RAEB-II; 10-
20% blasts in BM) were defined, and two more particular groups: MDS 
unclassified (for patients with neutropenia or thrombocytopenia alone) and MDS 
with 5q- syndrome (since this is a specific group with particular biology and a 
better prognosis) were introduced. On the other hand, CMML was excluded. 30  
However, the WHO classification did not include relevant information on 
cytogenetic abnormalities, one of the main prognostic factors in MDS patients. 
Also the threshold of 20% BM blasts count for defining AML is still debatable. In 
1996, the International Prognostic Scoring System (IPSS) based on known 
significant prognostic factors (% of blasts, number of cytopenias and type of 
cytogenetic abnormalities) defined four risk groups: Low, Intermediate I, 
Intermediate II and High (table 1.).31 Each risk group has different prognosis, as 
shown by survivals ranging between 0,4 to 5,7 years.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. IPSS for MDS: Diagnostic and Prognostic.  
From Greenberg, P. et al, Blood, 1997; 89:2079-88 
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Pathogenesis 
 
 MDS is a clonal and probably multi-step disease that results from genetic 
or epigenetic alterations in the myeloid hematopoietic stem cell and 
abnormalities in BM microenvironment. The molecular mechanisms underlying 
the genetic alterations are: chromosomal deletions (frequent) and translocations 
(rare), genetic mutations and epigenetic alterations. Cytogenetic abnormalities 
appear in 50% of primary MDS and 80% of the secondary cases and may 
influence clinical features, define prognosis and suggest therapeutic strategies. 
It is frequent to find deletions and monossomies in regions that may have tumor 
suppressor genes. However these tumor suppressor genes are not yet known.  
The loss of specific genes that affect cell cycle, apoptosis and hematopoiesis 
control contribute to MDS phenotype. The most common cytogenetic alterations 
are:  –5, 5q-, -7, 7q-, 11q-, 13q-, 17p- and 20q-. The del(5q) and –7/del (7q) are 
the most frequent. Interestingly del(5q) has a good prognosis due to the specific 
treatment with lenalidomide. Monosomy 7 and del (7q) have a particularly bad  
prognosis,32-35 as well as complex karyotypes (> 3 cytogenetic alterations).  
 MDS pathogenesis is also caused by abnormal bone marrow 
microenvironment that favours the development of the malignant clone.36 This 
microenvironment is composed not only by the stromal cells and intercellular 
matrix, that may be altered and induce abnormal adhesion patters, 
undifferentiation and apoptosis, leading to altered hematopoiesis, but also by 
pathological levels of locally secreted cytokines. MDS derived adherent cell 
layers produce high levels of TNF-α and IL-6.37 MDS therapy should target not 
only patterns in the transformed cell but also this aberrant environment. The 
angiogenesis patterns in haematological malignancies are not as well 
characterized as they are in solid tumors. However, it is known that 
angiogenesis in leukaemia and in MDS has an important role, since an 
increased vascular density is found in these diseases. Anti-angiogenic drugs 
like Thalidomide and Lenalidomide are already used in patients with some 
encouraging results, although its mechanism action is not fully understood.38   
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Treatment  
 
Treatments available for MDS patients are scarce and consist mainly in 
supportive care (transfusions), biologic response modifiers and chemo therapy. 
Transfusions are given to correct cytopenias like anemia and thrombocytopenia. 
In selected cases biologic response modifiers (like hematopoietic growth 
factors: EPO and G-CSF; and the synthetic androgen Danazol39) may 
ameliorate anemia. The benefit of low-intensity chemotherapy (5-azacytidine – 
AzaC) is not clearly demonstrated. High-intensity chemotherapy, is indicated in 
high risk patients and has an increased risk of morbidity and mortality: it can 
only be apply to fit patients and consists in standard chemotherapy for acute 
leukemia. It can be followed by hemopoietic stem cell transplantation (HSCT) in 
selected patients. Azatidine and decitabine were recently introduced in the 
clinical armamentarium and are very important to antagonize the 
hypermetilation of the promoter regions of cell cycle control found genes in 
MDS patients. Their clinical benefit, however, is still limited.  
As previously mentioned, many studies have already demonstrated the 
importance of angiogenesis in hematologic diseases such as MDS. It is known 
that MDS bone marrow has an increased vascularization and higher levels of 
angiogenic soluble factors, like Vascular Endothelial Growth Factor (VEGF), 
and its specific membrane receptors.40,41 Some clinical studies suggest that 
VEGF and VEGF receptors levels might correlate with disease 
aggressiveness.42    
 Based on this information, some alternative therapies have been 
considered in these disorders: anti-angiogenic (anti-VEGF antibody; 
Bevacizumab) and anti-apoptotic drugs (anti-TNF), Thalidomide and 
Lenalidomide. Thalidomide inhibits angiogenesis by interfering with both bFGF 
and VEGF action and inhibits the production of TNF-α by mRNA degradation. 
Thalidomide, and more recently Lenalidomide, are known to be effective in 
patients with 5q- syndrome and to induce not only clinical but also cytogenetic 
responses.  
 In general, the majority of MDS patients are over 60 years old and their 
therapeutic options remain very limited. The development of new target drugs 
able to stop disease progression by interfering with specific pathogenic 
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mechanisms is urgently needed. For that, it is first necessary to clarify the 
pathogenic mechanisms inherent to different MDS subtypes, and define 
patients which have higher probabilities to respond to specific treatments.  
MDS is an attractive pathogenic model to study disease progression 
towards leukaemia, especially because it has many different stages with 
specific features, during which the neoplastic clone grows and acquires different 
characteristics.  
 
 MDS is also a good model to study cell and microenvironment changes 
in bone marrow that may be involved in progression to acute myeloid leukemia. 
As MDS includes many disease subtypes, we can follow disease progression 
and understand the inherent mechanisms under leukemia development.  
 Because of this, it is important to characterize the angiogenic profile in 
patients with different subtypes of MDS and relate them with prognosis, disease 
evolution and therapeutic responses. The cytogenetic study in BM endothelial 
progenitor cells is extremely relevant to understand the role of vasculogenesis 
in this malignancy, the influence of endothelial cells upon hematopoiesis, their 
relationship with the neoplastic clone and the contribution of the endothelial 
compartment to an abnormal bone marrow phenotype in hematological tumors.    
 
Recently, in non-Hodgkin lymphoma, cytogenetic alterations in 
endothelial cells similar to the ones found in the neoplasic clone were 
described.43 These results suggest the existence of a common precursor 
between tumor cells and endothelial cells, or even endothelial cell differentiation 
though tumoral progenitor cell. Further examples of such process have not 
been identified in other tumors. Therefore, a close interaction between vascular 
and hematopoietic elements within the BM is crucial for the cell differentiation in 
normalcy as well as malignancy. A thorough understanding of the 
contribution/importance of the vascular BM compartment during leukemia 
progression from MDS is essential for the discovery of novel therapeutic 
strategies to treat these deadly diseases.    
 
 
 14 
2) Materials and methods  
 
Patient samples 
 
Bone marrow (BM) biopsies were obtained from 28 patients and were 
collected after informed consent, according to IPOFG-EPE guidelines. Study 
protocols were approved by the Institutional Review Board and Ethics 
Committee. Patients with MDS were 29 - 82 (median 67) years old and were 
diagnosed according to the International Prognostic Scoring System (IPSS) 
(see table 1). The study group was divided into 6 low-risk patients, 13 
intermediate-risk patients and 9 patients that were under MDS specific 
treatment at the time of analysis (we consider MDS therapeutics those 
consisting of Thalidomide, Danazol and Vidaza).  
Among these, 8 patients were diagnosed as primary MDS while 10 
patients were considered secondary MDS (if the disease occurred after 
chemotherapy and/or radiotherapy, for breast cancer, endometrial cancer, 
rectum carcinoma and neuroendocrine carcinoma). 
Mononuclear cells (BMNC) from the BM biopsies were isolated by Ficoll-
Hypaque (Sigma, St Louis, MO) density gradient centrifugation. After 
subsequently washing BMNC with phosphate-buffered saline/2mM of EDTA, 
cells were counted with the aid of a hemacytomer and then resuspended in 
30% of RPMI (GIBCO, Grand Island, NY) with 10% fetal bovine serum (FBS), 
1x antibiotic and antimycotic and 1x Glutamine (Complete Medium). Finally, 
BMNC were frozen in Complete Medium, 10% of DMSO and 60% of FBS and 
kept at -80ºC for further analysis.  
 
Flow cytometry analysis 
 
Fluorescence-activated cell-sorting (FACS) analysis was performed 
using a BD FACSCalibur flow cytometer (Becton, Dickinson), and was used to 
identify BM Hematopoietic Stem cells (HSC), Endothelial Progenitor Cells and 
endothelial cells. For FACS staining, approximately 1x106 cells of each BM 
sample were incubated with 10µl of FcR blocking reagent (Miltenyi Biotec), with 
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rotation at room temperature. After an incubation period of 15min, 5µl of the 
following fluorescent conjugate antibodies were added: CD133-PE (Miltenyi 
Biotec), ckit (CD117, Immunotech), CD34 (BD Pharmigen) and/or KDR-APC 
(RnD systems). Cells were incubated 45min, with rotation at room temperature. 
 
For determination of the BM apoptosis index, erythrocyte lysis was 
performed with RCLB reagent (Red cell lyses buffer) and cells were 
resuspended in 100µl of Annexin reagent buffer. For apoptosis identification it 
was applied 2µl of Annexin V- FITC antibody (BD Pharmingen) for 15 min at 
room temperature. For each sample it was acquired 50.000 cells.   
 
RNA extraction and cDNA synthesis  
 
RNA extraction from BMNCs was performed according to the following 
protocol: BMNCs were washed in serum-free RPMI, counted and homogenized 
in Trizol reagent (Invitrogene). The next steps were done with the cells placed 
on ice. Chloroform was mixed to the homogenized solution, incubated for 15min 
and after that centrifuged for 15min, 14000 rpm in a refrigerated (at 4ºC) 
centrifuge. The aqueous phase was collected to a new tube and isopropranol 
was added to precipitate RNA. The mixture was incubated for 15min, 
centrifuged for 15min, 14000 rpm at 4ºC, and the precipitated RNA obtained 
was washed in ethanol 70% and solubilized in DEPC water. Total RNA was 
quantified for each sample in a spectrophotometer (Beckman Du-650 (USA)). 
cDNA was synthesized according to the following protocol: a 13,5µl mix 
was prepared with 2ng/µl of RNA, 1µl of Random Primers and distilled water. 
After the annealing step of 10min at 70ºC, a mixture 4µl of buffer 10x, 4µl of 
dNTPs, 2µl of DTT co-factor, 1µl of SuperScriptII reverse transcriptase and 
0,5µl of RNase out inhibitor (Invitrogen), was added, making up  a final volume 
of 11,5µl. This mixture was incubated 1h30min/2hours at 37ºC and a final 
10min at 65ºC step to stop the enzymatic reaction. 
 To validate the presence of the new synthesized cDNA, BCR gene was 
amplified by PCR.  
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Quantitative RQ-PCR for TNF-α, TGF-β, PlGF and VEGF 
isoforms 
 
TNF-α, TGF-β, PlGF and VEGF isoforms (VEGF121, VEGF145, 
VEGF165 and VEGF189), mRNA expression was determined by quantitative 
real-time PCR. For TNF-α, TGF-β and PlGF mRNA expression  1µl of cDNA 
was used, 12,5µl of SYBR Green PCR Master Mix kit (Applied Biosystems, 
Foster City, CA), 0,75µl of each primer (Sigma), 0,5µl of BSA 2% and 9,5µl of 
distilled water in a final volume of 25µl. The relative expression level of each 
target mRNA was normalized to BCR expression. VEGF isoforms mRNA 
expression was determined based on specific primer and probes. PCR reaction 
contained 1µl of cDNA, 12,5µl of Taqman universal PCR master mix (Applied 
Biosystems), 0,75µl of each primer, 0,83µl of probe and 9,17µl of distilled water 
in a final volume of 25µl. A specific primer and probe set was used for the 
internal control gene, 18S. All reactions consisted of incubations at 50ºC for 2 
minutes, 95°C for 10 minutes, 45 cycles at 95°C for 15 seconds and 60°C for 1 
minute and were performed in Micro-Amp optical 96-well plates using the ABI 
Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, 
CA). Relative values were calculated by using a comparative cycle threshold 
(Ct) for each duplicate. The primer and probe sequences are listed in Table 2. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Primer pairs and probes used in real-time PCR experiments 
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VEGF quantification by ELISA  
 
Plasma samples from all the BM biopsies were obtained and VEGF 
levels were quantified by Enzyme-linked immunoadsorbent assay (ELISA) 
(Calbiochem, Dalmstadt, Germany), following the instructions of the 
manufacturer. Briefly, we added 100 µl of Assay Diluent RD1W to each well of a 
96-well plate coated with anti-human VEGF mouse monoclonal antibody. 
Afterwards, 100µl of each sample was applied to each well, plate was covered 
with the sealer provided and incubated at room temperature for 2hours. The 
wells containing sample and calibration samples were washed extensively with 
1X Wash Buffer afterwhich 200 µl of the VEGF Conjugate was added to each 
well. The Plate was incubated at room temperature for 2 hours, washed with 1X 
Wash Buffer and 200 µl of Substrate Solution were applied to each well. After 
an incubation period of 25 minutes at room temperature, 50 µl of Stop Solution 
was added, and finally absorbance was measured in each well using a 
spectrophotometric plate reader (Anthos Labtec, ELISA-Reader, Wals, Austria) 
at 450/540 nm. 
 
AC133+ cells isolation 
 
An attempt to identify a putative common origin for the different affected 
lineages in MDS BM. Hematopoietic and EPC were isolated from MDS patients 
harbouring different genetic markers. For example, BMNCs from patients with a 
del(20) (q11q13) cytogenetic alteration were washed in complete RPMI 
medium, resuspended and plated in a 1% gelatine-coated well, where they 
were left to recover. AC133+ cells were isolated using the mini-MACS 
immunomagnetic separation system from Miltenyi Biotec, following these 
procedures: we added 100 µl of FcR Blocking Reagent to total cells and 
resuspended them in 300 µl of BSA/0,1% PBS buffer. Cells were labeled by 
adding 100 µl CD133 MicroBeads, incubated for 45 minutes at 4−8 °C and 
afterwards they were washed with BSA/0,1% PBS buffer . The column used for 
the magnetic separation was placed in the magnetic field of a MACS Separator. 
Cell suspension was applied to the column, which was washed with buffer, 
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removed from separator and finally the fraction with magnetically AC133 
labelled cells was flushed out using the plunger supplied with the column.  
 
FISH analysis  
  
 AC133+ isolated cells were added in a small spot in glass microscope 
slide for fluorescence in situ hybridization (FISH). The isolated cell suspension 
was dried at 37ºC and then fixed with methanol/acetic acid (3:1) at room 
temperature. The commercial probe (Vysis, Downwers Grove, IL) LSI® 
D20S108 (20q12) (conjugated with spectrum orange fluorophore) used to 
detect del(20) (q11q13) in AC133+ cells, was applied at the hybridization area. 
The next step involved denaturation for 5 min at 80ºC and a hybridization step 
for 16hours at 37ºC.  Afterwards, glass microscope slide was washed in 
0,4xSSC/0,3%NP40 2 minutes at 73ºC, 2xSSC/0,1%NP40 for 30 seconds at 
room temperature and finally DAPI was applied to the glass microscope slide 
which was  visualized in a fluorescent microscope (Zeiss AxioImager.Z1 
microscope) (using the 63x objective).  
 
Immunohistochemistry 
 
To determine whether EPC shared malignant cell markers/genetic 
alterations, immunohistochemistry detection for HoxA9 was performed on 
isolated AC133+ cells already submitted to FISH analysis (described above). 
Cells were rehydrated by washing in decreasing concentrations of ethanol for 5 
min each (100%, 90%, 70%, 30%). Cells were washed with PBS1x for 5 min, 
after which they were incubated for 5 min at room temperature with 0,2% Triton 
reagent. After membrane permeabilization, the cells were blocked with BSA 
0,1% for 45 min  at room temperature.. Cells were incubated with HoxA9 (Santa 
Cruz Biotechnology) diluted at 1:50 overnight at 4ºC, washed with PBS the next 
day and incubated with donkey anti-goat Alexa 594 (Molecular probes) diluted 
at 1:500 in 0,2% Triton reagent for 1 hour at room temperature. After secondary 
antibody incubation sample was washed in PBS, mounted in a medium 
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composed with Vectashild and Dapi and examined under fluorescent 
microscope (63x objective).  
 
The same cells were studied for the two markers and in each marker 
glass microscope slide coordinates were registered. In the end we could 
compare different markers in the same cells based in their position.    
 
 Normal and malignant BM from murine carginogenesis model and BM 
biopsies from MDS patients were fixed in 10% buffered formalin for a minimum 
of 24 hours and decalcified in a rapid bone decalcifier (Perudo00-008; Eurobio, 
Les Ulis, France) for 3 hours and paraffin embedded. For the immunostaining 
2µm sections, togheter with thymus, spleen and lungs from murine model, were 
deparaffinized in xylene and rehydrated in decreasing concentrations of 
ethanol.  
 Slides for normal and malignant BM, thymus, spleen and lungs from mice 
were stained with hematoxilin-eosin. Antigen retrieval for slides for VEGF, CD31 
and vwF (Von Willebrand factor) staining was performed as follows: 15 min in 
Tris-EDTA at 98ºC for VEGF, 6 minutes in citrate buffer in a pressure cooker for 
CD31 and 20 min in pepsin at 37ºC for vwF. VEGF (Dako Cytomation) was 
used diluted at 1:50, CD31 (Dako Cytomation) was used at 1:20 and vwF 
(Novocastra) at 1:30. Then, were incubated 1 hour at 4°C and final staining was 
performed in a Dako Thechmate500 Plus (Dako Cytomation) at room 
temperature. The number of vwF and CD31 immunostained blood vessels in 
tissue sections was quantified in four different fields at 400x magnification. The 
intensity of the VEGF immunoreactive reaction was graded in four different 
fields at 100x magnification (0, no immunoreactivity, 1, weak intensity, 2, 
moderate intensity, 3, strong intensity).  
 
Mice 
 
For the establishment of an in vivo MDS model, FVB/N mice (15 males 
and 15 females) were divided in two groups: 10 control mice and 20  sublethally 
irradiated (3Gy; 300rad) mice in a three irradiation cycle with one month of 
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interval between them. Every month after the last irradiation, the levels of 
circulating EPC (Flk+Sca+) in peripheral blood were quantified by FACS. Briefly, 
blood was centrifuged and plasma was collected for VEGF ELISA analysis. 
Then, cells were incubated 1hour with Sca-1-FITC and Flk-1-PE (BD 
Pharmigen) in PBS/2% FBS at 4ºC, with rotation. In the end cells were washed 
and read in the flow cytometer. 
 
 
 
 
 
 
 
Statistical analysis 
 
The data were analyzed using SigmaStat software from Jandell 
Corporation (San Rafael, CA, USA). Groups were compared using double 
comparison procedures (Rank Sum Test) and pairwise multiple comparison 
procedures (Dunn’s method).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of irradiation cycles in the BM carcinogenesis model.   
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3) Results 
  
Angiogenesis Profile of MDS 
 
Increased progenitor cells in MDS bone marrow  
 
To evaluate the hematopoietic and EPC content in  MDS bone marrows 
FACS analysis was performed in order to detect single positive or double/triple 
positive  CD34+, CD117+, CD133+ and KDR+ cells. As shown in Figure 1 there 
was a significant increase in CD34+, CD117+ and CD133+ progenitor cells, 
CD133+KDR+ endothelial progenitor cells and KDR+ endothelial cells in 
intermediate risk patients. These data suggest there is an increase in the BM 
progenitor cell pool, in particular EPC in the intermediate risk group the 
compared to the low risk category and also those undergoing some therapy. 
There is also the suggestion of increase vasculature (KDR+ cells) with disease 
progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Increased progenitor cells in 
MDS bone marrow and progenitor cells 
levels correlate with MDS therapeutic. 
Bone marrow mononuclear cells were 
analysed by flow cytometry: CD34+ cells 
(A), CD117+ cells (B), CD133+ cells (C), 
KDR+ cells (D) and CD133+/KDR+ cells (E). 
p=0,384 p=0,250 
p=0,414 
p=0,011 p=0,018 
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Progenitor cells levels are found to correlate with MDS 
treatment  
 
We used the same analysis described previously in patients under MDS 
therapeutics, like Vidaza, Danazol and Thalidomide, to evaluate MDS bone 
marrow response to treatment and eventual recover during therapeutic 
intervention. The frequency of CD34+, CD117+ and CD133+ progenitor cells, 
CD133+KDR+ endothelial progenitor cells and KDR+ endothelial cells in these 
patients was significantly lower those detected in than intermediate risk 
patients. Although done in a small group of patients, MDS therapeutics seem to 
reduce BM angiogenesis (as determined by the number of KDR+ cells) that was 
initiated by disease (Figure 1). This observation was exploited further by 
determining BM microvessel density in the different patient groups. 
 
Apoptosis in MDS bone marrow cells 
 
 One of the most important characteristics of MDS BM is the presence of 
single or multiple cytopenias in mature and immature cells. We analysed the 
apoptotic index in CD34+, CD117+ and CD133+ BM progenitor cells, 
CD133+KDR+ endothelial progenitor cells and KDR+ endothelial cells using an 
apoptotic surface marker AnnexinV. There were a constantly higher apoptosis 
levels in intermediate risk patients both in AC133+ progenitor cells and KDR+ 
endothelial cells in MDS bone marrow (Figure 2). Therefore, this progenitor cell 
population is more frequent in intermediate risk patients (Figure 1), although 
these cells undergo higher turnover (increased apoptosis rate). Although we 
analysed only two patients under MDS treatment, it is interesting to notice that 
the overall BM apoptotic index is lower in treated patients when compared with 
risk groups.  
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VEGF levels are reduced with MDS therapeutic 
 
 Having mesured an increase in CD133+KDR+ EPC and KDR+ endothelial 
cells in MDS bone marrow we determined VEGF protein levels in bone marrow 
plasma samples as it is a main angiogenic factor. Surprisingly, VEGF levels 
among risk groups were similar but in patients under treatment were 
significantly lower (Figure 3A). These data although obtain from a very small 
number of treated patients, suggest the response of MDS patients to treatment 
involves reducing angiogenesis stimulation within the bone marrow. 
Nevertheless, vascular changes in MDS patients BM have been reported. 
Therefore, we also performed a more detailed study about mRNA expression of 
VEGF isoforms (VEGF121, VEGF145, VEGF165 and VEGF189). While VEGF121 
showed very weak variation, VEGF189 appeared to be highest in MDS 
intermediate risk patients and the two patients treated with Danazol (Figure 3C).  
 
 
 
 
 
 
 
 
 
Figure 2. Apoptosis in MDS bone marrow cells. Apoptosis index was measured 
by flow cytometry with AnnexinV. Intermediate risk group has more apoptotic 
AnnexinV+/CD133+ cells (A) and AnnexinV+/KDR+ cells (B).  
A 
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TNF-α and TGF-β mRNA expression 
 
 In order to investigate the putative contribution of other angiogenic 
factors present in MDS BM, or their regulation in an abnormal BM, we analysed 
the levels of expression of TNF-α, TGF-β and PlGF (member of the VEGF 
family that binds only VEGFR1, Flt-1) mRNA. We observed a tendency for 
increased TNF-α and TGF-β mRNA in intermediate risk patients (Figure 4), but 
no relevant differences in PlGF mRNA expression (data not shown). These 
results support the idea of an abnormal BM microenvironment in MDS patients 
and suggest the higher apoptotic indexes in mature cells seen in more 
advanced diseased stages, may result from the action of TNF-α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. TNF-alpha, TGF-beta mRNA expression. TNF-α/cell 
and TGF-β/cell mRNA expression was determined by Real-
time PCR.  
Figure 3. Total VEGF levels are lowered with MDS therapeutic. VEGF levels were 
measured by ELISA and mRNA expression of VEGF isoforms by quantitative Real-time 
PCR. MDS patients under treatment have a lower VEGF production per cell. Results are 
prescuted as the proportion between the less abundant isoforms, VEGF121 and VEGF189, 
and the most abundant isoform, VEGF165. 
C B 
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Blood vessel quantification  
 
 To quantify blood vessels in BM of patients with MDS we used vwF and 
CD31 (vwF is produced in megakaryocytes and endothelium and CD31, 
PECAM-1, identifies platelet endothelial cell adhesion molecule) markers, and 
VEGF as angiogenesis indicators (Figure 5). As shown in figure 6, vessel 
number is higher in intermediate risk patients when compared with the lower 
risk. Patients under treatment have no significant decrease in this parameter.  
CD31 is an endothelial surface marker and it is augmented in the BM of MDS 
patients as we have seen through KDR+ cells. As mentioned before, these 
results suggest there is an increase in BM vasculature with disease 
progression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
B A 
Figure 5. Examples of blood vessel 
staining in BM samples from MDS 
patients with: vwF (A) and CD31 (B). 
VEGF is augmented in patients with 
more advanced disease (C). 
40x 
40x 
40x 
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Increased EPC in patients that received radiotheraphy    
 
 Secondary MDS is caused by chemotherapy or radiotherapy treatment 
for other diseases. In our group of MDS patients the ones treated previously 
with radiotherapy showed high levels of  CD133+ progenitor cells, CD133+KDR+ 
endothelial progenitor cells and KDR+ endothelial cells (Figure 7). These results 
suggest that radiotherapy treatment changes BM microenviroment potentiating 
a secondary MDS and BM angiogenesis. Notably, unpublished data in our 
laboratory has shown that irradiation induces TNF-α production in BM cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Increased EPC in patients that had received radiotherapy (alone or 
in combination with radiotherapy). Secondary MDS patients were analysed for 
CD133+ cells, KDR+ cells and CD133+/KDR+ cells in Bone Marrow.  
Figure 6. Blood vessel quantification MVD with angiogenic markers: 
vwF, CD31 and VEGF 
 
p=0,234 
p=0,048 
p=0,605 
p=0,029 
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Endothelial progenitor cells are malignant cells in MDS 
 
 Taken together, our data (although obtain from a small group of patients) 
suggests some of the cellular and molecular changes that take place in MDS 
BM involve modulation of the vascular compartment. Increased EPC and EC 
are detected in the intermediate risk patients; surprisingly, they do not 
completely correlate with total VEGF levels, but are accompanied by a specific 
isoform. As in other hematologic diseases, modulation of the BM vascular 
content in MDS may be interpreted in two ways: either EC and EPC increase in 
response to BM angiogenesis regulation/increase and sustain/support the 
expansion of malignant clones, or EPC/EC are part of the malignant 
transformation process.  
 
To address the question if EPC are malignant cells in MDS BM we 
isolated CD133+ cells from a sample of a low-risk patient with a cytogenetic 
abnormality del(20q). FISH analyses showed that AC133+ cells are already 
transformed in early MDS stages. Immunohistochemistry analyses for 
endothelial marker HoxA9 were made in the same cells and, as shown in figure 
8 and 9, suggest that EPC and possibly other progenitors (AC133+HoxA9+) are 
already transformed, ie, malignant,  in MDS bone marrow.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. FISH for del(20q) in MDS AC133+ cells. AC133+ cells are malignant cells in MDS bone 
marrow.  
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Murine Carcinogenesis Model 
 
In this mouse BM Carcinogenesis model established in our laboratory, 
BM leukemia incidence (at the end of the assay; 11 months after the last 
irradiation) was approximately 63% in the irradiated group with an equal 
thymoma and acute leukemia incidence (Figure 11A).  About 37% of the 
irradiated mice presented signs of disease 2,5 months after the last irradiation 
(early disease group) while the other 26% presented signs of disease 7,2 
months after the last irradiation (late disease group). Of importance to the work 
presented in this thesis (focussing on pre-leukemia), we analised the early 
disease group further. Regardless, the two groups of mice that developed BM 
disease had a decreased number of circulating EPC when compared with the 
no disease group. In the early disease group the decrease was more evident 
(Figure 12). In addition, mice with no disease presented low levels of VEGF 
compared with the two groups that developed tumors (Figure 11B). Taken 
together, these results suggest that BM EPC may modulate the onset of 
haematological diseases and BM microenvironment and correlate with the time 
of disease. 
 
 
 
 
 
Figure 9. Immunohistochemistry for HoxA9 in MDS AC133+ cells.  
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Figure 11. Tumor incidence (A) and VEGF levels in circulation (B) between irradiated 
and non-irradiated mice. 
A B 
Figure 10. Normal and Malignant Bone 
marrow, tymus, spleen and lungs stain 
with hematoxilin-eosin. 
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Figure 12. Circulating EPC levels correlate with time of disease onset. 
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4) Discussion 
 
 Angiogenesis induction is one of the crucial characteristics in tumors 
pathophysiology. In haematological diseases like MDS, angiogenesis and 
angiogenic inducers have an important contribution for disease development. 
Microvessel density (MVD) measures angiogenesis through 
immunohistochemical biological markers, giving considerable information about 
disease progression and prognosis. A significant increase in BM MVD in MDS 
and AML32 and a higher expression in angiogenic factors such VEGF44, bFGF, 
TNF-α45, Ang1, Ang2 and VEGFR246 were demonstrated. Most of the factors 
are probably secreted by neoplastic hematopoietic cells.   
 Several studies have already demonstrated the importance of BM-
derived EPC in tumor vasculature. In patients with AML, AC133+ progenitors 
with known cytogenetic lesions are augmented in peripheral blood. This could 
indicate a possible role of AC133+ progenitors, and subsequently EPC, in BM 
abnormal vasculogenesis and leukemia progression.47 It was also reported that 
in peripheral blood of MDS patients circulating EP and circulating EC are 
augmented and there is a direct correlation with MVD in BM.48 Only a few 
studies have suggest a contribution of EPC, particularly immature cells with the 
EPC marker AC133, in BM abnormal vasculature in MDS patients. MDS BM 
also expressed VEGF levels that correlate with these immature cells which 
revealed a probably contribution of these cells in disease dissemination.49 Our 
results support these data. First, progenitor cell pool is augmented in patients 
with a more aggressive phenotype, in particular EPC and EC suggesting 
changes in vasculature. Immunohostochemistry analysis supported the idea of 
angiogenesis increase particularly with disease progression. Abnormal levels of 
angiogenic factors such total VEGF and VEGF189, TGF-β and TNF-α change 
BM microenvironment, VEGF189 appears to be the most important VEGF 
isoform in this malignancy and augmented levels of TNF-α in BM relate with 
higher apoptotic indexes are observed in progenitor and mature cells of 
advanced risk stages.  
 Our results revealed that AC133+/HoxA9+ immature cells have already a 
malignant transformation in MDS BM patients contributing for abnormal 
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vasculature and malignancy development. It is not yet clarified if apoptosis is 
affecting only normal or also transformed cells in MDS BM. Genetic lesions in 
BM-derived EPC can affect bone marrow vascularization in different ways 
contributing for the malignant process: EC differentiated from transformed EPC 
will affect vessels formation and structure; altered EC may also contribute for 
hematopoiesis deregulation though abnormal secretion of angiogenic factors or 
different signalling in cell-cell interaction. However, increase of transformed 
EPC and EC can be a response to support the malignant clone development.   
 More recently, our unpublished data suggests that Thalidomide may 
have the ability of induce EPC apoptosis. Thalidomide is known to have an anti-
proliferative and pro-apoptotic effect in tumor cells by reducing cell synthesis 
and interfering with VEGF action.50 We shown that MDS patients under MDS 
specific treatment, like Thalidomide, have reduced EPC an d EC, angiogenic 
factors and apoptosis. This anti-angiogenic drug reduces vascularization that 
was initiated by disease. In our group of patients under MDS specific treatment 
angiogenesis is reduced and probably the potential MDS progression to acute 
leukemia. 
 Interestingly, we observed that patients with secondary MDS caused by 
radiotherapy show a modulation of the vascular BM compartment by increased 
EPC and EC. This result is supported by our murine irradiation model in which 
almost 40% of mice present disease sings shortly after irradiation. Our group 
has shown that TNF-α is stimulated by BM radiation, which may be in the origin 
of increased apoptotic rates in BM cells changing BM microenvironment 
homeostasis.   
  The murine carcinogenesis model is extremely relevant to test the 
importance of all these findings in a true experimental setting, first, because it is 
an in vivo model and then because we can exploit changes that happen within 
BM since disease onset, allowing us to control disease progression thoughout 
time. After irradiation, mice BM cells suffer cellular and molecular damages that, 
in most cases, result in leukemia development. In initial months after radiation 
BM microenvironment is similar to MDS BM, a “pre-leukemic” stage: cell 
number is reduced, the number of circulating EPC decreases in the peripheral 
blood and there are increased levels of VEGF. 
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 In conclusion our results suggest that BM EPC may act as a “pre-
malignant” clone and may also have an important role in the progression of 
haematological diseases modulating BM angiogenesis. Particularly in MDS, the 
BM vasculature and angiogenic soluble factors regulation correlates with 
disease progression, hematopoietic deregulation and development to acute 
leukemia.  
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Future perspectives 
 
 The clinical relevance of this study relies in the importance of identifying 
EPC as a malignant cell in BM disease development, and according to our 
results in a murine carcinogenesis model, the possible use of measuring 
circulating EPC as a disease marker in some haematological diseases, with 
prognostic relevance.  
It is also clear that angiogenesis is a conditional feature for MDS 
progression and its reduction, through anti-angiogenic drugs, may delay 
disease progression. It would be interesting to test the impact of Thalidomide in 
the murine carcinogenesis model, as well as the effect of blocking some 
angiogenic factors such as TNF-α and the specific isoform VEGF189 during 
disease progression. Peripheral blood and BM analysis for EPC levels and 
other angiogenesis markers will answer how the BM is responding. This would 
allow us to clarify and understand BM regulation and the mechanisms that 
contribute to the development of haematological malignancies.  
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